首页> 美国卫生研究院文献>Annals of Oncology >Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

【2h】

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

机译：克唑替尼在MET改变的晚期透明细胞肉瘤患者中的活性和安全性：欧洲癌症研究与治疗组织II期临床试验90101 CREATE

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundClear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor crizotinib in patients with advanced or metastatic CCSA.

机译：背景透明细胞肉瘤（CCSA）是一种孤儿恶性肿瘤，特征在于特定的t（12; 22）易位，导致EWSR1基因重排和MET的过度表达。我们前瞻性地研究了酪氨酸激酶抑制剂克唑替尼在晚期或转移性CCSA患者中的疗效和安全性。

著录项

期刊名称 Annals of Oncology
作者
P Schöffski; A Wozniak; S Stacchiotti; P Rutkowski; J -Y Blay; L H Lindner; S J Strauss; A Anthoney; F Duffaud; S Richter; V Grünwald; M G Leahy; P Reichardt; J Sufliarsky; W T van der Graaf; R Sciot; M Debiec-Rychter; T van Cann; S Marréaud; M Lia; T Raveloarivahy; L Collette; S Bauer;
展开▼
作者单位

展开▼
年(卷),期 -1(28),12
年度 -1
页码 3000–3008
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
clear-cell sarcoma MET gene EWSR1 gene rearrangement tyrosine kinase inhibitor crizotinib;

机译：透明细胞肉瘤;MET基因;EWSR1基因重排;酪氨酸激酶抑制剂;克唑替尼;

相似文献

外文文献
中文文献
专利

1. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE' [J] . Sch?ffski, Wozniak, Stacchiotti, Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第12期

机译：高级清除细胞肉瘤患者的活动和安全性与达到改变的患者：欧洲研究和治疗癌症期二期试验90101'创造'
2. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE' [J] . Schoffski P., Wozniak A., Kasper B., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第3期

机译：TFE3重排的肺泡软骨肉瘤患者中肝硬化患者的活性和安全性：欧洲癌症研究和治疗组织（EORTC）II期试验90101'Create'
3. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE' [J] . Schoffski P., Wozniak A., Kasper B., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第3期

机译：TFE3重排的肺泡软骨肉瘤患者中肝硬化患者的活性和安全性：欧洲癌症研究和治疗组织（EORTC）II期试验90101'Create'
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Communication preferences, expectations of benefit, and symptom burdens among advanced cancer patients and partners during patient participation in phase I trials [D] . Hlubocky, Fay J. 2010

机译：患者参加I期试验期间，晚期癌症患者及其伴侣之间的沟通偏好，受益期望以及症状负担
6. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ [O] . P Schöffski, A Wozniak, S Stacchiotti, -1

机译：克唑替尼在MET改变的晚期透明细胞肉瘤患者中的活性和安全性：欧洲癌症研究与治疗组织II期临床试验90101 CREATE
7. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ [O] . P. Schöffski, A. Wozniak, S. Stacchiotti, 2017

机译：具有符合符合符合变更的临床清除细胞肉瘤患者的活动和安全性：欧洲研究和治疗癌症期间试验90101'Create'的欧洲研究和治疗组织

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

摘要

著录项

相似文献

相关主题

期刊订阅